Stephane Wong

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

François-Xavier Mahon, Carla Boquimpani, Dong‐Wook Kim et al. · Annals of Internal Medicine · 2018 · 132 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Phosphoinositide 3-kinase signaling is essential for ABL oncogene–mediated transformation of B-lineage cells

Michael G. Kharas, Jonathan A. Deane, Stephane Wong et al. · Blood · 2004 · 85 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Regulation of the Oncogenic Activity of BCR-ABL by a Tightly Bound Substrate Protein RIN1

Daniel Afar, Limin Han, Jami McLaughlin et al. · Immunity · 1997 · 84 citations · Full text

Medicine, Biochemistry, Molecular Biology +8

Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene

Lu Q. Le, Janusz H. Kabarowski, Stephane Wong et al. · Cancer Cell · 2002 · 56 citations · Full text

Medicine, Hematology, Oncology +12

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz et al. · Blood · 2012 · 56 citations

Medicine, Hematology, Pharmacology +15